Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Wnt/Beta-Catenin Signaling and Prostate Cancer Therapy Resistance
Yunshin Yeh, Qiaozhi Guo, Zachary M. Connelly, et al.
Advances in experimental medicine and biology (2019), pp. 351-378
Closed Access | Times Cited: 68

Showing 1-25 of 68 citing articles:

Association of the Epithelial–Mesenchymal Transition (EMT) with Cisplatin Resistance
Milad Ashrafizadeh, Ali Zarrabi, Kiavash Hushmandi, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 11, pp. 4002-4002
Open Access | Times Cited: 219
The Role of Notch, Hedgehog, and Wnt Signaling Pathways in the Resistance of Tumors to Anticancer Therapies
Vivek Kumar, Mohit Vashishta, Lin Kong, et al.
Frontiers in Cell and Developmental Biology (2021) Vol. 9
Open Access | Times Cited: 177
Targeting signaling pathways in prostate cancer: mechanisms and clinical trials
Yundong He, Weidong Xu, Yu‐Tian Xiao, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 128
Wnt pathway modulators in cancer therapeutics: An update on completed and ongoing clinical trials
Ann Neiheisel, Manpreet Kaur, Nancy Ma, et al.
International Journal of Cancer (2021) Vol. 150, Iss. 5, pp. 727-740
Open Access | Times Cited: 73
Quercetin and Its Nano-Scale Delivery Systems in Prostate Cancer Therapy: Paving the Way for Cancer Elimination and Reversing Chemoresistance
Yaseen Hussain, Sepideh Mirzaei, Milad Ashrafizadeh, et al.
Cancers (2021) Vol. 13, Iss. 7, pp. 1602-1602
Open Access | Times Cited: 67
Inhibition of DCLK1 sensitizes resistant lung adenocarcinomas to EGFR-TKI through suppression of Wnt/β-Catenin activity and cancer stemness
Rui Yan, Xiaona Fan, Zeru Xiao, et al.
Cancer Letters (2022) Vol. 531, pp. 83-97
Open Access | Times Cited: 43
Treatment strategies and drug resistance mechanisms in adenocarcinoma of different organs
Xing Peng, Shuo Wang, Yu Cao, et al.
Drug Resistance Updates (2023) Vol. 71, pp. 101002-101002
Open Access | Times Cited: 25
WNT5a Signaling through ROR2 Activates the Hippo Pathway to Suppress YAP1 Activity and Tumor Growth
Keshan Wang, Fen Ma, Seiji Arai, et al.
Cancer Research (2023) Vol. 83, Iss. 7, pp. 1016-1030
Open Access | Times Cited: 24
Blocking the WNT/β-catenin pathway in cancer treatment:pharmacological targets and drug therapeutic potential
Xi Zhao, Yunong Ma, Jiayang Luo, et al.
Heliyon (2024) Vol. 10, Iss. 16, pp. e35989-e35989
Open Access | Times Cited: 10
Cell Plasticity and Prostate Cancer: The Role of Epithelial–Mesenchymal Transition in Tumor Progression, Invasion, Metastasis and Cancer Therapy Resistance
Sofia Papanikolaou, Aikaterini Vourda, Spyros A. Syggelos, et al.
Cancers (2021) Vol. 13, Iss. 11, pp. 2795-2795
Open Access | Times Cited: 46
Wnt/β-catenin signal transduction pathway in prostate cancer and associated drug resistance
Chunyang Wang, Qi Chen, Huachao Xu
Discover Oncology (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 43
Dioscin: A review on pharmacological properties and therapeutic values
Shinjini Bandopadhyay, Uttpal Anand, Vijaykumar Shivaji Gadekar, et al.
BioFactors (2021) Vol. 48, Iss. 1, pp. 22-55
Closed Access | Times Cited: 43
Down‐regulated LINC00115 inhibits prostate cancer cell proliferation and invasion via targeting miR‐212‐5p/FZD5/Wnt/β‐catenin axis
Naixiong Peng, Zejian Zhang, Yaomin Wang, et al.
Journal of Cellular and Molecular Medicine (2021) Vol. 25, Iss. 22, pp. 10627-10637
Open Access | Times Cited: 35
miR-541-3p enhances the radiosensitivity of prostate cancer cells by inhibiting HSP27 expression and downregulating β-catenin
Zhenhua He, Fuhui Shen, Ping Qi, et al.
Cell Death Discovery (2021) Vol. 7, Iss. 1
Open Access | Times Cited: 33
Nuclear receptor NURR1 functions to promote stemness and epithelial-mesenchymal transition in prostate cancer via its targeting of Wnt/β-catenin signaling pathway
Xingxing Zhang, Haolong Li, Yuliang Wang, et al.
Cell Death and Disease (2024) Vol. 15, Iss. 3
Open Access | Times Cited: 5
Direct interaction of β‐catenin with nuclear ESM1 supports stemness of metastatic prostate cancer
Ke‐Fan Pan, Wei‐Jiunn Lee, Chun‐Chi Chou, et al.
The EMBO Journal (2020) Vol. 40, Iss. 4
Open Access | Times Cited: 35
Therapeutic Potential of Exosomes in Pulmonary Fibrosis
Linshen Xie, Ye Zeng
Frontiers in Pharmacology (2020) Vol. 11
Open Access | Times Cited: 33
Prostate Cancer Stem Cells: Biology and Treatment Implications
Ioannis M. Koukourakis, Kalliopi Platoni, Vassilis Kouloulias, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 19, pp. 14890-14890
Open Access | Times Cited: 11
Systematic multi-omics investigation of androgen receptor driven gene expression and epigenetics changes in prostate cancer
Lin Li, Kyung Hyun Cho, Xiuping Yu, et al.
Computers in Biology and Medicine (2025) Vol. 189, pp. 110000-110000
Closed Access
Whole genome sequencing of 378 prostate cancer metastases reveals tissue selectivity for mismatch deficiency with potential therapeutic implications
Daniël J. Vis, Sander Palit, Marie Corradi, et al.
Genome Medicine (2025) Vol. 17, Iss. 1
Open Access
The Role of PHLDA3 in Cancer Progression and Its Potential as a Therapeutic Target
Walied Kamel, Jayaraman Krishnaraj, Rieko Ohki
Cancers (2025) Vol. 17, Iss. 7, pp. 1069-1069
Open Access
Unravelling the molecular mechanisms of prostate cancer evolution from genotype to phenotype
Dali Tong
Critical Reviews in Oncology/Hematology (2021) Vol. 163, pp. 103370-103370
Closed Access | Times Cited: 26
Recent advances of β-catenin small molecule inhibitors for cancer therapy: Current development and future perspectives
Panpan Yang, Yumeng Zhu, Qinwen Zheng, et al.
European Journal of Medicinal Chemistry (2022) Vol. 243, pp. 114789-114789
Closed Access | Times Cited: 17
YTHDF2 protein stabilization by the deubiquitinase OTUB1 promotes prostate cancer cell proliferation via PRSS8 mRNA degradation
Xuefeng Zhao, Suli Lv, Neng Li, et al.
Journal of Biological Chemistry (2024) Vol. 300, Iss. 4, pp. 107152-107152
Open Access | Times Cited: 3
YBX1 as a therapeutic target to suppress the LRP1-β-catenin-RRM1 axis and overcome gemcitabine resistance in pancreatic cancer
Borui Li, Faliang Xing, Jingyi Wang, et al.
Cancer Letters (2024) Vol. 602, pp. 217197-217197
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top